How we isolated the TRK oncogene

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I was very surprised to see in an issue of the NEJM earlier this year that Loxo Oncology had developed a selective TRK inhibitor, larotrectinib, and even more surprised to learn that TRK fusions occur in about 1 percent of all human cancers.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

Login